CG Oncology (NASDAQ:CGON) Price Target Raised to $75.00

CG Oncology (NASDAQ:CGON) had its target price lifted by Truist Financial from $66.00 to $75.00 in a research note released on Tuesday, Marketbeat reports. They currently have a buy rating on the stock.

CGON has been the subject of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a research report on Wednesday, January 21st. Morgan Stanley set a $93.00 price target on shares of CG Oncology in a report on Friday, January 9th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $82.00 price objective on shares of CG Oncology in a report on Monday, January 12th. Royal Bank Of Canada boosted their target price on CG Oncology from $61.00 to $73.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. Finally, Wedbush began coverage on CG Oncology in a report on Thursday, December 11th. They issued an “outperform” rating and a $70.00 price target for the company. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $68.58.

CG Oncology Trading Down 3.6%

Shares of CGON stock opened at $51.62 on Tuesday. The company has a market capitalization of $4.16 billion, a P/E ratio of -25.30 and a beta of 1.32. The business’s 50 day moving average is $47.01 and its two-hundred day moving average is $39.78. CG Oncology has a twelve month low of $14.80 and a twelve month high of $57.88.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.57) EPS for the quarter, hitting the consensus estimate of ($0.57). The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.07 million. As a group, equities analysts predict that CG Oncology will post -1.31 earnings per share for the current fiscal year.

Insider Buying and Selling at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $41.43, for a total value of $41,430.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director James Mulay sold 11,145 shares of the firm’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $52.47, for a total transaction of $584,778.15. The SEC filing for this sale provides additional information. 7.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CG Oncology

Large investors have recently bought and sold shares of the stock. Whittier Trust Co. of Nevada Inc. purchased a new stake in shares of CG Oncology in the fourth quarter valued at $27,000. Winthrop Capital Management LLC acquired a new position in CG Oncology in the 2nd quarter valued at about $38,000. Strengthening Families & Communities LLC acquired a new position in CG Oncology in the 3rd quarter valued at about $40,000. Comerica Bank lifted its holdings in CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in shares of CG Oncology by 15.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock worth $85,000 after purchasing an additional 433 shares during the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.